Frontiers in medicine · 2026
Direct interleukin-6 inhibitor olokizumab in the treatment of polymyalgia rheumatica: a case series.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meshkov Alexey D, Maslyanskiy Alexey L, Chudinov Anton L, Ilivanova Elena P, Smitienko Ilya O, Novikov Pavel I, Torgashina Anna V, Arseniev Evgeniy V, Khovasova Natalia O, Naumov Anton V, Tkacheva Olga N, Zotkin Evgeny G
Аннотация
OBJECTIVE: To describe the experience of using olokizumab (OKZ) in patients with polymyalgia rheumatica (PMR) who have contraindications or an inadequate response to methotrexate and require steroid-sparing therapy, and to analyze treatment outcomes in this cohort.
METHODS: A case series included 23 patients with PMR [including giant-cell arteritis (GCA) in 9 patients] treated with OKZ. The assessment of disease activity was carried out using the PMR-activity score (AS) index, as well as laboratory parameters [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. The statistical analysis was performed using the StatTech v program. 4.7.3.
RESULTS: Olokizumab therapy resulted in a significant decrease in PMR activity: the PMR-AS index decreased from 18.6 (14.2-24.4) to 3.01 (1.62-6.09) points by 12-24th weeks. Most patients (86.3%) who received therapy achieved remission or low disease activity. Laboratory parameters have also improved: ESR values decreased from 32.00 (20.00-47.00) to 7.00 (5.00-8.50) mm/h, and CRP - from 14.10 (8.10-40.80) to 0.85 (0.30-2.15) mg/l. The steroid dose decreased from 7.5 (5.0-15.0) to 2.50 (0.00-2.50) mg/day by week 24. The results listed above were statistically significant (p < 0.05). The disease duration of less than 36 months at the time of initiation of therapy proved to be a significant predictor of achieving low PMR activity (AUC = 0.912; p = 0.024).
CONCLUSION: Olokizumab demonstrated high efficacy in reducing the activity of PMR, laboratory markers of inflammation and the dose of steroids in patients with inefficacy or intolerance to methotrexate.
METHODS: A case series included 23 patients with PMR [including giant-cell arteritis (GCA) in 9 patients] treated with OKZ. The assessment of disease activity was carried out using the PMR-activity score (AS) index, as well as laboratory parameters [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)]. The statistical analysis was performed using the StatTech v program. 4.7.3.
RESULTS: Olokizumab therapy resulted in a significant decrease in PMR activity: the PMR-AS index decreased from 18.6 (14.2-24.4) to 3.01 (1.62-6.09) points by 12-24th weeks. Most patients (86.3%) who received therapy achieved remission or low disease activity. Laboratory parameters have also improved: ESR values decreased from 32.00 (20.00-47.00) to 7.00 (5.00-8.50) mm/h, and CRP - from 14.10 (8.10-40.80) to 0.85 (0.30-2.15) mg/l. The steroid dose decreased from 7.5 (5.0-15.0) to 2.50 (0.00-2.50) mg/day by week 24. The results listed above were statistically significant (p < 0.05). The disease duration of less than 36 months at the time of initiation of therapy proved to be a significant predictor of achieving low PMR activity (AUC = 0.912; p = 0.024).
CONCLUSION: Olokizumab demonstrated high efficacy in reducing the activity of PMR, laboratory markers of inflammation and the dose of steroids in patients with inefficacy or intolerance to methotrexate.